Open AccessControl of gastric acid hypersecretion in the management of patients with Zollinger‐Ellison syndrome
Author(s) -
Metz David C.,
Pisegna Joseph R.,
Fishbeyn Vitaly A.,
Benya Richard V.,
Jensen Robert T.
Publication year - 1993
Publication title -
world journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.115
H-Index - 148
eISSN - 1432-2323
pISSN - 0364-2313
DOI - 10.1007/bf01655106
Subject(s) - zollinger ellison syndrome , medicine , gastrinoma , gastric acid , omeprazole , lansoprazole , parathyroidectomy , gastroenterology , abdominal surgery , parenteral nutrition , proton pump inhibitor , gastrectomy , stomach , secretion , parathyroid hormone , gastrin , cancer , calcium
During the last 5 years important advances have occurred in the control of gastric acid hypersecretion in Zollinger‐Ellison syndrome (ZES). The increased availability of potent gastric acid antisecretory agents such as histamine H 2 ‐receptor antagonists and more recently the H + K + ‐ATPase inhibitors such as omeprazole and lansoprazole have made it possible to medically control acid secretion in all patients. Increased understanding of the variation in antisecretory drug dosage between individual patients has led to identification of criteria to ensure effective antisecretory control and to the recognition of subgroups of patients who require special monitoring. Effective regimens for parenteral antisecretory control during surgery have been established. The importance of parathyroidectomy in patients with multiple endocrine neoplasia type I with ZES and the possible usefulness of highly selective vagotomy have been investigated. We review here the new data that led to increased understanding in each of these areas from our studies and studies by others.